



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

MARCH 30, 2022

PTAS

MATTHEW J. BRESNAHAN
WILSON SONSINI GOODRICH & ROSATI
650 PAGE MILL ROAD
PALO ALTO, CA 94304

507197183

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 03/24/2022

REEL/FRAME: 059394/0922
NUMBER OF PAGES: 4

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 56884-786.601

ASSIGNOR:
FECTEAU, JESSIE-FARAH

DOC DATE: 03/23/2022

ASSIGNOR:
RENSHAW, MARK

DOC DATE: 03/21/2022

ASSIGNOR:
FRANSSON, JOHAN

DOC DATE: 03/21/2022

ASSIGNOR:
LAURENT, OLIVIER

DOC DATE: 03/17/2022

ASSIGNOR:
BARNETT, BURTON

DOC DATE: 03/21/2022

ASSIGNEE:
PROMETHEUS BIOSCIENCES, INC.
9410 CARROLL PARK DRIVE
SAN DIEGO, CALIFORNIA 92121

APPLICATION NUMBER:

FILING DATE: 02/16/2022

PATENT NUMBER:

ISSUE DATE:

PCT NUMBER: US2022016565

TITLE: ANTI-CD30L ANTIBODIES AND USES THEREOF

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT

Docket Number 56884-786.601

The undersigned:

- | | | | |
|--|--|--|---|
| 1. Jessie-Farah FECTEAU
9410 Carroll Park Drive
San Diego, CA 92121 | 2. Mark RENSHAW
9410 Carroll Park Drive
San Diego, CA 92121 | 3. Johan FRANSSON
9410 Carroll Park Drive
San Diego, CA 92121 | 4. Olivier LAURENT
9410 Carroll Park Drive
San Diego, CA 92121 |
| 5. Burton BARNETT
9410 Carroll Park Drive
San Diego, CA 92121 | | | |

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to **PROMETHEUS BIOSCIENCES, INC.**, a corporation incorporated under the laws of the State of Delaware, having a place of business at 9410 Carroll Park Drive, San Diego, California, 92121 (USA), (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

ANTI-CD30L ANTIBODIES AND USES THEREOF

- for which a PCT application serial number **PCT/US2022/016565** was filed on February 16, 2022 in the United States Receiving Office of the Patent Cooperation Treaty

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, , cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.

5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT

Docket Number 56884-786.601

IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:

Date: 03-23-2022 Jessie Fecteau
Jessie-Farah FECTEAUDate: 3/21/22 Mark Renshaw
Mark RENSHAWDate: 3/21/22 Johan Fransson
Johan FRANSSONDate: 03/17/22 Olivier Laurent
Olivier LAURENTDate: 3/21/22 Burton Barnett
Burton BARNETT

RECEIVED AND AGREED TO BY ASSIGNEE:

PROMETHEUS BIOSCIENCES, INC.

Date: 03/23/2022 Signature: Feng YE
Name: Feng YE
Title: Vice President, Intellectual Property



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JULY 14, 2021

PTAS

WILSON SONSINI GOODRICH & ROSATI
650 PAGE MILL ROAD
PALO ALTO, CA 94304

506761904

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 07/13/2021

REEL/FRAME: 056830/0728
NUMBER OF PAGES: 7

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: 56884-786.101

ASSIGNOR:

PECTEAU, JESSIE-FARAH

DOC DATE: 02/26/2021

ASSIGNOR:

RENSHAW, MARK

DOC DATE: 02/25/2021

ASSIGNOR:

FRANSSON, JOHAN

DOC DATE: 02/25/2021

ASSIGNOR:

LAURENT, OLIVIER

DOC DATE: 02/25/2021

ASSIGNEE:

PROMETHEUS BIOSCIENCES, INC.
9410 CARROLL PARK DR.
SAN DIEGO, CALIFORNIA 92121

APPLICATION NUMBER: 63150373

FILING DATE: 02/17/2021

PATENT NUMBER:

ISSUE DATE:

TITLE: ANTI-CD30L ANTIBODIES AND USES THEREOF

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT

Docket Number 56884-786.101

The undersigned:

1. Jessie-Farah FECTEAU
Escondido, California (US)
2. Mark RENSHAW
San Diego, California (US)
3. Johan FRANSSON
San Diego, California (US)
4. Olivier LAURENT
San Diego, California (US)

(the "Inventor(s)"), desire to assign the entire right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to Prometheus Biosciences, Inc., a corporation incorporated under the laws of the State of Delaware, having a place of business at 9410 Carroll Park Drive, San Diego, California 92121 (US), (the "Assignee"), and Assignee desires to acquire such right, title and interest, all on the terms and conditions set forth in this Patent Assignment.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Inventor(s) to have been received in full from said Assignee:

1. Said Inventor(s) have invented certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

ANTI-CD30L ANTIBODIES AND USES THEREOF

- for which application serial number 63/150,373 was filed on February 17, 2021 in the United States Patent and Trademark Office

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Inventor(s) do hereby sell, assign, transfer and convey unto said Assignee the entire right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions, heretofore conceived, made or discovered, whether jointly or severally, by said Inventor(s) (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Inventor(s) hereby covenant and agree to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Inventor(s) shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Inventor(s) in providing such cooperation shall be paid for by said Assignee.


4. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Inventor(s), their respective heirs, legal representatives and assigns.


5. Said Inventor(s) hereby warrant, represent and covenant that said Inventor(s) have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Inventor(s) hereby request that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignee, or its successors and assigns, for the sole use of said Assignee, its successors, legal representatives and assigns.

7. This instrument will be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

PATENT ASSIGNMENT		Docket Number 56884-786.101
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below.		
Date: _____	_____ Jessie-Farah FECTEAU	
Date: <u>2/25/2021</u>	<u>Mark Renshaw</u> Mark RENSHAW	
Date: _____	_____ Johan FRANSSON	
Date: _____	_____ Olivier LAURENT	
RECEIVED AND AGREED TO BY ASSIGNEE: PROMETHEUS BIOSCIENCES, INC.		
Date: _____	Signature: _____ Name: Laurens Kruidenier Title: Chief Scientific Officer	

PATENT ASSIGNMENT		Docket Number 56884-786.101
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:		
Date: _____	_____ Jessie-Farah FECTEAU	
Date: _____	_____ Mark RENSHAW	
Date: 02/25/2021	 _____ Johan FRANSSON	
Date: _____	_____ Olivier LAURENT	
RECEIVED AND AGREED TO BY ASSIGNEE: PROMETHEUS BIOSCIENCES, INC.		
Date: _____	Signature: _____ Name: Laurens Kruidenier Title: Chief Scientific Officer	

PATENT ASSIGNMENT		Docket Number 56884-786.101
IN WITNESS WHEREOF, said Inventor(s) have executed and delivered this instrument to said Assignee as of the dates written below:		
Date: _____	_____ Jessie-Farah FECTEAU	
Date: _____	_____ Mark RENSHAW	
Date: _____	_____ Johan FRANSSON	
Date: <u>25 FEB 21</u>	 _____ Olivier LAURENT	
RECEIVED AND AGREED TO BY ASSIGNEE: PROMETHEUS BIOSCIENCES, INC.		
Date: <u>2/26/21</u>	Signature:  Name: Laurens Kruidenier Title: Chief Scientific Officer	



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUNE 9, 2023

PTAS

WILSON SONSINI GOODRICH & ROSATI
650 PAGE MILL ROAD
PALO ALTO, CA 94304

507944756

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 06/06/2023

REEL/FRAME: 063881/0585
NUMBER OF PAGES: 3

BRIEF: SHARED INTEREST ASSIGNMENT 25%

DOCKET NUMBER: 56884-786

ASSIGNOR:

PROMETHEUS BIOSCIENCES, INC.

DOC DATE: 04/13/2023

ASSIGNEE:

DR. FALK PHARMA GMBH
LEINENWEBERSTRASSE 5
FREIBURG IM BREISGAU, GERMANY 79108

APPLICATION NUMBER: 17822598

FILING DATE: 08/26/2022

PATENT NUMBER:

ISSUE DATE:

TITLE: ANTI-CD30L ANTIBODIES AND USES THEREOF

APPLICATION NUMBER: 63150373

FILING DATE: 02/17/2021

PATENT NUMBER:

ISSUE DATE:

TITLE: ANTI-CD30L ANTIBODIES AND USES THEREOF

APPLICATION NUMBER:

FILING DATE: 02/16/2022

PATENT NUMBER:

ISSUE DATE:

PCT NUMBER: US2022016565

TITLE: ANTI-CD30L ANTIBODIES AND USES THEREOF

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

CORPORATE TO CORPORATE CONFIRMATORY PATENT ASSIGNMENT

Docket Number: 56884-786

PROMETHEUS BIOSCIENCES, INC., a corporation incorporated under the laws of the State of Delaware, having a place of business at 3050 Science Park Road, San Diego, CA 92121 (USA) (the "Assignor"), has agreed to assign 25% of the Assignor's right, title and interest in and to the Inventions and Assigned Patents (each, as defined below) to DR. FALK PHARMA GMBH, a German Corporation registered with the Commercial Register of the Amtsgericht Freiburg under HRB 3266 and having offices at Leinenweberstraße 5, 79108 Freiburg im Breisgau, Germany., (the "Partial Assignee"), and Partial Assignee desires to confirm such right, title and interest, has been transferred.

NOW, THEREFORE, in consideration of good and valuable consideration acknowledged by said Assignor to have been received in full from said Partial Assignee:

1. Said Assignor confirms the previous assignment of 25% of the Assignor's right, title and interest in and to certain new and useful inventions and improvements disclosed in the following patent(s) and patent application(s):

ANTI-CD30L ANTIBODIES AND USES THEREOF

- United States Provisional Patent Application No. 63/150,373 filed February 17, 2021
- International Application No. PCT/US2022/016565 filed February 16, 2022
- Taiwanese Patent Application No. 111105667 filed February 16, 2022
- Argentinean Patent Application No. P220100318 filed February 16, 2022
- United States Patent Application No. 17/822,598 filed August 26, 2022

(the "Listed Patent(s)"). As used herein: "Assigned Patents" means (a) the Listed Patent(s), (b) all Patents that share priority with or claim priority to or from the Listed Patent(s), including each and every Patent that is a divisional, substitution, continuation, continuation-in-part, non-provisional, or national phase application of any of the Listed Patent(s), (c) all Patents applied for on an invention disclosed within the Patents included in foregoing subclauses (a)-(b), (d) each and every Patent granting, issuing or reissuing from any of the foregoing under subclauses (a)-(c), (e) each and every reissue, reexamination, renewal or extension of any kind of any of the foregoing under subclauses (a)-(d), and (f) each and every Patent filed outside the United States and corresponding to any of the foregoing under subclauses (a)-(e). "Patents" means (i) patents, certifications of inventions, inventor's certificates and other forms of protection granted on any invention in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, including those filed under the Paris Convention for the Protection of Industrial Property, The Patent Cooperation Treaty or otherwise, and (ii) applications therefor (whether provisional, converted provisional, utility, design, plant, utility model, non-provisional or otherwise).

2. Said Assignor does hereby confirm assignment unto said Partial Assignee 25% of the Assignor's right, title and interest (a) in and to the Assigned Patents, including the right to claim priority to and from said Assigned Patents; (b) in and to the inventions disclosed in the Assigned Patents, and in and to all embodiments of the inventions (the "Inventions") and (c) in and to all claims for past, present and future infringement of the Assigned Patents, including all rights to sue for and to receive and recover for Partial Assignee's own use all past, present, and future lost profits, royalties, and damages of whatever nature recoverable from an infringement of the Assigned Patents.

3. Said Assignor hereby covenants and agrees to cooperate with said Partial Assignee to enable said Partial Assignee to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by said Assignor shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said Partial Assignee (a) for perfecting in said Partial Assignee the right, title and interest herein conveyed; (b) for filing, prosecuting or maintaining any of the Assigned Patents; (c) for filing, prosecuting or maintaining applications for reissuance of any said Assigned Patents; (d) for interference or other priority proceedings involving said Assigned Patents or Inventions; and (e) for legal proceedings involving said Inventions or Assigned Patents, including without limitation reissues and reexaminations, IPRs, opposition and other post-grant proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that reasonable expenses incurred by said Assignor in providing such cooperation shall be paid for by said Partial Assignee.

4. The terms and covenants of this assignment shall inure to the benefit of said Partial Assignee, its successors, and assigns, and shall be binding upon said Assignor and its assigns.

5. Said Assignor hereby warrants, represents and covenants that Assignor has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

6. Said Assignor hereby requests that any Assigned Patents issuing or granting in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued or granted in the name of the Assignor and Partial Assignee, or their successors and assigns, for the sole use of said Assignor and Partial Assignee, its successors and assigns.


7. This instrument will be interpreted and construed in accordance with the laws of the State of California without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

CORPORATE TO CORPORATE CONFIRMATORY PATENT ASSIGNMENT

Docket Number: 56884-786

IN WITNESS WHEREOF, said Assignor has executed and delivered this instrument to said Partial Assignee as of the date written below:


AGREED TO BY ASSIGNOR: PROMETHEUS BIOSCIENCES, INC.

Date: April 13, 2023Signature: 

Name: Feng YE

Title: Vice President, Intellectual Property

RECEIVED AND AGREED TO BY PARTIAL ASSIGNEE: DR. FALK PHARMA GMBH

Date: 17 APR 2023Signature: 

Name:

Title: Managing Director
DR. FALK PHARMA